LML134

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Circadian Rhythm DisordersHealthy Volunteers

Phase 1

First-in-human Study to Assess the Safety and Pharmacokinetics of LML134 in Healthy Volunteers

CompletedNCT02334449

Novartis PharmaceuticalsHealthy Volunteers

Start: 2015-02-28End: 2016-02-29Updated: 2016-10-27

Phase 2

A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder

TerminatedNCT03141086

Novartis PharmaceuticalsCircadian Rhythm Disorders

Start: 2017-07-26End: 2018-09-12Updated: 2021-01-05